There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Andrew Huynh |
| Institution: | Austin Health |
| Department: | Medical and Cognitive Research Unit |
| Country: | |
| Proposed Analysis: | Our study aims to better understand the relationships between hypertension, obesity and dementia. 1. Is obesity/adiposity associated with Alzheimer’s disease biomarkers (blood and PET)? 2. Is obesity/or adiposity associated with changes in brain volume? 3. Is obesity or adiposity associated with change in cognition? 4. Are associations between obesity and brain structure or cognitive performance mediated by Alzheimer’s disease, or by other mechanisms (e.g. cerebrovascular disease, inflammation)? Our plan with data analysis is to: 1. Test the association between baseline adiposity measures (Body Mass Index) and baseline Aβ PET in normal cognition, MCI and AD participants, adjusting for covariates including age, diabetes, hypertension, cholesterol. 2. Test the relationship between change in adiposity measures (e.g. weight loss) and change in Aβ burden over time. 3. Test the cross sectional and longitudinal associations between adiposity measures and brain volume (MRI). 4. If significant associations are identified, determine whether associations between adiposity and brain changes (Aβ burden and MRI) are mediated or influenced by adipokines (e.g. leptin, adiponectin) inflammatory markers (e.g. C-reactive protein) or pro-inflammatory cytokines. For this we would be looking for the following data (cross-sectional and longitudinal) For this we would be looking for the following data (cross-sectional and longitudinal) • Baseline characteristics o Gender o Age o Height (in centimetres if possible) o Weight (in kilograms if possible) – change in weight over time o APOE status o Past medical history including hypertension, diabetes mellitus, dyslipidemia, smoking history and ischemic heart disease • Cognitive diagnosis o Change in cognition during study o Change in MMSE o Change in Cognitive dementia rating (CDR) • MRI o Change in total grey matter size o Change in hippocampal size o Change in white matter hyperintensities • PET o Change in amyloid SUVR (in centiloids if possible) • CSF o Change in Abeta 42 o Change in Abeta 42/40 ratio • Inflammatory markers o Change in C reactive protein (CRP) o Change in leptin, adiponectin levels Thank you in advance for your assistance. |
| Additional Investigators | |
| Investigator's Name: | Paul Yates |
| Proposed Analysis: | Our study aims to better understand the relationships between hypertension, obesity and dementia. 1. Is obesity/adiposity associated with Alzheimer’s disease biomarkers (blood and PET)? 2. Is obesity/or adiposity associated with changes in brain volume? 3. Is obesity or adiposity associated with change in cognition? 4. Are associations between obesity and brain structure or cognitive performance mediated by Alzheimer’s disease, or by other mechanisms (e.g. cerebrovascular disease, inflammation)? Our plan with data analysis is to: 1. Test the association between baseline adiposity measures (Body Mass Index) and baseline Aβ PET in normal cognition, MCI and AD participants, adjusting for covariates including age, diabetes, hypertension, cholesterol. 2. Test the relationship between change in adiposity measures (e.g. weight loss) and change in Aβ burden over time. 3. Test the cross sectional and longitudinal associations between adiposity measures and brain volume (MRI). 4. If significant associations are identified, determine whether associations between adiposity and brain changes (Aβ burden and MRI) are mediated or influenced by adipokines (e.g. leptin, adiponectin) inflammatory markers (e.g. C-reactive protein) or pro-inflammatory cytokines. For this we would be looking for the following data (cross-sectional and longitudinal) • Baseline characteristics o Gender o Age o Height (in centimetres if possible) o Weight (in kilograms if possible) – change in weight over time o APOE status o Past medical history including hypertension, diabetes mellitus, dyslipidemia, smoking history and ischemic heart disease • Cognitive diagnosis o Change in cognition during study o Change in MMSE o Change in Cognitive dementia rating (CDR) • MRI o Change in total grey matter size o Change in hippocampal size o Change in white matter hyperintensities • PET o Change in amyloid SUVR (in centiloids if possible) • CSF o Change in Abeta 42 o Change in Abeta 42/40 ratio • Inflammatory markers o Change in C reactive protein (CRP) o Change in leptin, adiponectin levels Thank you in advance for your assistance. Obesity, hypertension, Alzheimer's disease, PET, MRI, CSF |
